Grant ID RP180880
Awarded On August 24, 2018
Title Targeting BRAF- and RAS-Mutant Cancers by Small Molecule-Induced Proteolysis of ERK1/2
Program Academic Research
Award Mechanism High Impact/High Risk
Institution/Organization The University of Texas at Austin
Principal Investigator/Program Director Kevin Dalby
Cancer Sites Colorectal, Lung and Bronchus, Melanoma
Contracted Amount $200,000
Lay Summary

Melanoma is a deadly form of skin cancer killing approximately ten thousand Americans per year, with a disproportionate number residing in Texas. Diagnoses are expected to increase by 26% over the next 16 years, and will have a proportionally greater impact on young adults as well as on African-American and Hispanic populations in Texas. There is an urgent need for novel drugs for treating patients with drug-resistant melanomas. The focus of this proposal is to address this unmet medical need and to develop an entirely novel therapeutic modality with a triple mechanism of action against an enzyme called ERK which is critical for melanoma. These mechanisms are – 1) inhibiting ERK activation,...

Read More